HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval

Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality shine through his mute world.

By FiercePharma · Apr 25, 2026 · via FiercePharma
Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval

Image: FiercePharma

Tags
pipelineformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso
PipelineFiercePharma ↗
Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso
The once-daily HIV treatment regimen offers a new mechanism of action in the HIV treatment market.…
Apr 23, 2026
Racing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset
PipelineFierceBiotech ↗
Racing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset
Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person sy…
Apr 23, 2026
Roche’s Neuroimmunology Gambit: Enspryng Pushes Into MOGAD, Fenebrutinib Faces Scrutiny
Pipeline
Roche’s Neuroimmunology Gambit: Enspryng Pushes Into MOGAD, Fenebrutinib Faces Scrutiny
Roche’s Enspryng cut MOGAD relapse risk by 68%, a pivotal step toward the first FDA-approved therapy for the d…
Apr 23, 2026